Search Results - "Vo, Josh N"

Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer by Xiao, Lanbo, Parolia, Abhijit, Qiao, Yuanyuan, Bawa, Pushpinder, Eyunni, Sanjana, Mannan, Rahul, Carson, Sandra E., Chang, Yu, Wang, Xiaoju, Zhang, Yuping, Vo, Josh N., Kregel, Steven, Simko, Stephanie A., Delekta, Andrew D., Jaber, Mustapha, Zheng, Heng, Apel, Ingrid J., McMurry, Lisa, Su, Fengyun, Wang, Rui, Zelenka-Wang, Sylvia, Sasmal, Sanjita, Khare, Leena, Mukherjee, Subhendu, Abbineni, Chandrasekhar, Aithal, Kiran, Bhakta, Mital S., Ghurye, Jay, Cao, Xuhong, Navone, Nora M., Nesvizhskii, Alexey I., Mehra, Rohit, Vaishampayan, Ulka, Blanchette, Marco, Wang, Yuzhuo, Samajdar, Susanta, Ramachandra, Murali, Chinnaiyan, Arul M.

“…The switch/sucrose non-fermentable (SWI/SNF) complex has a crucial role in chromatin remodelling 1 and is altered in over 20% of cancers 2 , 3 . Here we…”
Get full text

The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma by Vo, Josh N., Wu, Yi-Mi, Mishler, Jeanmarie, Hall, Sarah, Mannan, Rahul, Wang, Lisha, Ning, Yu, Zhou, Jin, Hopkins, Alexander C., Estill, James C., Chan, Wallace K. B., Yesil, Jennifer, Cao, Xuhong, Rao, Arvind, Tsodikov, Alexander, Talpaz, Moshe, Cole, Craig E., Ye, Jing C., Bergsagel, P. Leif, Auclair, Daniel, Cho, Hearn Jay, Robinson, Dan R., Chinnaiyan, Arul M.

“…Multiple myeloma is the second most common hematological malignancy. Despite significant advances in treatment, relapse is common and carries a poor prognosis…”
Get full text

Functional and Mechanistic Interrogation of BET Bromodomain Degraders for the Treatment of Metastatic Castration-resistant Prostate Cancer by Kregel, Steven, Malik, Rohit, Asangani, Irfan A, Wilder-Romans, Kari, Rajendiran, Thekkelnaycke, Xiao, Lanbo, Vo, Josh N, Soni, Tanu, Cieslik, Marcin, Fernadez-Salas, Ester, Zhou, Bing, Cao, Xuhong, Speers, Corey, Wang, Shaomeng, Chinnaiyan, Arul M

“…The bromodomain and extraterminal (BET)-containing proteins (BRD2/3/4) are essential epigenetic coregulators for prostate cancer growth. BRD inhibitors have…”
Get full text

The Landscape of Circular RNA in Cancer by Vo, Josh N., Cieslik, Marcin, Zhang, Yajia, Shukla, Sudhanshu, Xiao, Lanbo, Zhang, Yuping, Wu, Yi-Mi, Dhanasekaran, Saravana M., Engelke, Carl G., Cao, Xuhong, Robinson, Dan R., Nesvizhskii, Alexey I., Chinnaiyan, Arul M.

“…Circular RNAs (circRNAs) are an intriguing class of RNA due to their covalently closed structure, high stability, and implicated roles in gene regulation…”
Get full text

Virus-positive Merkel Cell Carcinoma Is an Independent Prognostic Group with Distinct Predictive Biomarkers by Harms, Kelly L, Zhao, Lili, Johnson, Bryan, Wang, Xiaoming, Carskadon, Shannon, Palanisamy, Nallasivam, Rhodes, Daniel R, Mannan, Rahul, Vo, Josh N, Choi, Jae Eun, Chan, May P, Fullen, Douglas R, Patel, Rajiv M, Siddiqui, Javed, Ma, Vincent T, Hrycaj, Steven, McLean, Scott A, Hughes, Tasha M, Bichakjian, Christopher K, Tomlins, Scott A, Harms, Paul W

“…Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma that can be divided into two classes: virus-positive (VP) MCC, associated with…”
Get full text

Viral Status Predicts the Patterns of Genome Methylation and Decitabine Response in Merkel Cell Carcinoma by Harms, Paul W., Verhaegen, Monique E., Vo, Josh N., Tien, Jean C., Pratt, Drew, Su, Fengyun, Dhanasekaran, Saravana M., Cao, Xuhong, Mangelberger, Doris, VanGoor, Julia, Choi, Jae Eun, Ma, Vincent T., Dlugosz, Andrzej A., Chinnaiyan, Arul M.

“…Merkel cell carcinoma (MCC) is an aggressive cutaneous neuroendocrine carcinoma that is classified as Merkel cell polyomavirus-positive (virus positive [VP])…”
Get full text

Clinical, genomic, and epigenomic analyses of H3K27M-mutant diffuse midline glioma long-term survivors reveal a distinct group of tumors with MAPK pathway alterations by Roberts, Holly J., Ji, Sunjong, Picca, Alberto, Sanson, Marc, Garcia, Mekka, Snuderl, Matija, Schüller, Ulrich, Picart, Thiébaud, Ducray, François, Green, Adam L., Nakano, Yoshiko, Sturm, Dominik, Abdullaev, Zied, Aldape, Kenneth, Dang, Derek, Kumar-Sinha, Chandan, Wu, Yi-Mi, Robinson, Dan, Vo, Josh N., Chinnaiyan, Arul M., Cartaxo, Rodrigo, Upadhyaya, Santhosh A., Mody, Rajen, Chiang, Jason, Baker, Suzanne, Solomon, David, Venneti, Sriram, Pratt, Drew, Waszak, Sebastian M., Koschmann, Carl

Get full text

Author Correction: Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer by Xiao, Lanbo, Parolia, Abhijit, Qiao, Yuanyuan, Bawa, Pushpinder, Eyunni, Sanjana, Mannan, Rahul, Carson, Sandra E., Chang, Yu, Wang, Xiaoju, Zhang, Yuping, Vo, Josh N., Kregel, Steven, Simko, Stephanie A., Delekta, Andrew D., Jaber, Mustapha, Zheng, Heng, Apel, Ingrid J., McMurry, Lisa, Su, Fengyun, Wang, Rui, Zelenka-Wang, Sylvia, Sasmal, Sanjita, Khare, Leena, Mukherjee, Subhendu, Abbineni, Chandrasekhar, Aithal, Kiran, Bhakta, Mital S., Ghurye, Jay, Cao, Xuhong, Navone, Nora M., Nesvizhskii, Alexey I., Mehra, Rohit, Vaishampayan, Ulka, Blanchette, Marco, Wang, Yuzhuo, Samajdar, Susanta, Ramachandra, Murali, Chinnaiyan, Arul M.

Get full text

Development of an orally bioavailable CDK12/13 degrader and induction of synthetic lethality with AKT pathway inhibition by Chang, Yu, Wang, Xiaoju, Yang, Jianzhang, Tien, Jean Ching-Yi, Mannan, Rahul, Cruz, Gabriel, Zhang, Yuping, Vo, Josh N., Magnuson, Brian, Mahapatra, Somnath, Cho, Hanbyul, Dhanasekaran, Saravana Mohan, Wang, Cynthia, Wang, Zhen, Zhou, Licheng, Zhou, Kaijie, Zhou, Yang, Zhang, Pujuan, Huang, Weixue, Xiao, Lanbo, Liu, Weihuang Raymond, Hamadeh, Rudana, Su, Fengyun, Wang, Rui, Miner, Stephanie J., Cao, Xuhong, Cheng, Yunhui, Mehra, Rohit, Ding, Ke, Chinnaiyan, Arul M.

“…Cyclin-dependent kinases 12/13 play pivotal roles in orchestrating transcription elongation, DNA damage response, and maintenance of genomic stability…”
Get full text

Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer by Qiao, Yuanyuan, Choi, Jae Eun, Tien, Jean C, Simko, Stephanie A, Rajendiran, Thekkelnaycke, Vo, Josh N, Delekta, Andrew D, Wang, Lisha, Xiao, Lanbo, Hodge, Nathan B, Desai, Parth, Mendoza, Sergio, Juckette, Kristin, Xu, Alice, Soni, Tanu, Su, Fengyun, Wang, Rui, Cao, Xuhong, Yu, Jiali, Kryczek, Ilona, Wang, Xiao-Ming, Wang, Xiaoju, Siddiqui, Javed, Wang, Zhen, Bernard, Amélie, Fernandez-Salas, Ester, Navone, Nora M, Ellison, Stephanie J, Ding, Ke, Eskelinen, Eeva-Liisa, Heath, Elisabeth I, Klionsky, Daniel J, Zou, Weiping, Chinnaiyan, Arul M

“…Multi-tyrosine kinase inhibitors (MTKIs) have thus far had limited success in the treatment of castration-resistant prostate cancer (CRPC). Here, we report a…”
Get full text

Abstract 975: Functional CRISPR screen towards identifying novel epigenetic co-factors of oncogenic AR-activity by Parolia, Abhijit, Xiao, Lanbo, Vo, Josh N., Cieslik, Marcin, Cao, Xuhong, Chinnaiyan, Arul M.

“…Abstract Prostate cancer (PCa) is the second leading cause of cancer-related mortality in North American men. In recent years, there has been mounting evidence…”
Get full text

Abstract 3288: The landscape of circular RNA in cancer by Vo, Josh N., Zhang, Yajia, Shukla, Sudhanshu, Xiao, Lanbo, Robinson, Dan, Wu, Yi-Mi, Gao, Sisi, Engelke, Carl, Cao, Xuhong, Nesvizhskii, Alexey, Chinnaiyan, Arul

“…Abstract Circular RNAs (circRNAs) are an intriguing class of RNA due to their covalently closed structure, relatively high stability, and implicated roles in…”
Get full text

Abstract 4153: Therapeutic targeting autophagy to sensitize cancer immunotherapy in various cancer types by Qiao, Yuanyuan, Choi, Jae E., Vo, Josh N., Tien, Jean C., Wang, Lisha, Xiao, Lanbo, Simko, Stephanie A., Delekta, Andrew D., Hodge, Nathan B., Desai, Parth, Juckette, Kristin, Xu, Alice, Su, Fengyun, Wang, Rui, Cao, Xuhong, Wang, Xiaoju, Wang, Xiaoming, Siddiqui, Javed, Wang, Zhen, Bernard, Amélie, Fernandez-Salas, Ester, Navone, Nora M., Ding, Ke, Eskelinen, Eeva-Liisa, Heath, Elisabeth I., Klionsky, Daniel J., Zou, Weiping, Chinnaiyan, Arul M.

“…Abstract Although cancer immunotherapy has revolutionized cancer treatment, patient response to immunotherapy remains varied. Despite progress, the mechanisms…”
Get full text